DERM - NASDAQ

Journey Medical Corporation

DERM·NASDAQ

$6.02

+2.0%

HealthcareDrug Manufacturers - Specialty & Generic

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$165.68M

EPS-0.4700

P/E Ratio-16.52

Earnings Date08/11/2026

94.59M

Assets

18%

3Y-10.0%

5Y+82.0%

10Y-70.0%

62.74M

Total Liabilities

3Y-29.0%

5Y+51.0%

10Y-4.0%

31.85M

Total Equity

59%

3Y+88.0%

5Y+209.0%

10Y-87.0%

Journey Medical Corporation Funding & Solvency Profile

DERM · NASDAQ

Current Assets

Cash & Cash Equivalents24.09M

Net Receivables29.78M

Inventory9.62M

Other Current Assets3.38M

Total Current Assets67 M

Non-Current Assets

Property, Plant & Equipment111.00K

Goodwill & Intangible Assets27.61M

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets111 K

Total Assets

94.59M

Financial Health Analysis

Current Ratio

1.79x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

1.97x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

29 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

71% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Journey Medical Corporation Balance Sheet

DERM • NASDAQ

Journey Medical Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	24.1M	20.3M	27.4M	32M	49.1M	8.2M	4.8M	105M	295.9M	41.8M	107.2M	55.4M
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	208.1M	255.1M	210.1M	107.5M	41.8M
Cash & Short-Term Investments	24.1M	20.3M	27.4M	32M	49.1M	8.2M	4.8M	313M	551M	251.9M	214.7M	97.2M
Net Receivables	29.8M	10.2M	15.2M	28.2M	23.1M	23.9M	19M	5.7M	52K	21.4M	0.0	7.3M
Accounts Receivables	29.8M	10.2M	15.2M	28.2M	23.1M	23.9M	19M	0.0	0.0	0.0	0.0	0.0
Inventory	9.6M	14.4M	10.2M	14.2M	9.9M	1.4M	857K	8.4M	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	0.0	1.7M	655K	0.0	0.0	0.0	0.0	0.0
Other Current Assets	3.4M	3.2M	3.6M	3.3M	2.4M	0.0	0.0	8.3M	5.6M	10.6M	2.5M	1M
Total Current Assets	66.9M	48.2M	56.5M	77.7M	84.5M	35.2M	25.3M	335.4M	556.6M	284M	217.2M	105.5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	111K	199K	101K	189K	89K	175K	89K	1.2M	1.4M	1.1M	386K	192K
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	771K	771K	771K	771K	771K
Intangible Assets	27.6M	31.9M	20.3M	27.2M	12.6M	15M	7.4M	952K	1.1M	1.1M	1.1M	3.5M
Goodwill & Intangible Assets	27.6M	31.9M	20.3M	27.2M	12.6M	15M	7.4M	1.7M	1.9M	1.9M	1.9M	4.3M
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3M	0.0	24.6M	1M	66.5M
Tax Assets	0.0	0.0	0.0	0.0	0.0	1.5M	1.1M	0.0	194K	194K	194K	816K
Other Non-Current Assets	0.0	0.0	6K	95K	150K	6K	6K	3M	656K	841K	1.2M	976K
Total Non-Current Assets	27.7M	32.1M	20.4M	27.5M	12.8M	16.7M	8.6M	8.9M	4.2M	28.6M	4.7M	72.8M
Total Assets	94.6M	80.2M	76.8M	105.2M	97.3M	51.9M	33.9M	344.3M	560.8M	312.6M	221.9M	178.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	9.4M	16.6M	18.1M	39.6M	23.4M	1.9M	2M	15.9M	15.1M	13.5M	9.2M	5.6M
Accounts Payable	9.3M	16.1M	16.1M	37M	22.8M	2M	2.1M	15.9M	15.1M	13.5M	9.2M	5.6M
Other Payables	70K	588K	2.1M	2.7M	589K	-100K	-100K	-15.9M	-15.1M	-13.5M	-9.2M	-5.6M
Accrued Expenses	0.0	3.4M	16.5M	10.1M	2.7M	19M	14.3M	0.0	0.0	0.0	0.0	0.0
Short Term Debt	101K	625K	3M	2.9M	812K	4.5M	0.0	0.0	4.6M	3M	1.1M	635K
Capital Lease Obligations (Current)	0.0	83K	99K	83K	98K	85K	83K	0.0	0.0	0.0	0.0	0.0
Tax Payables	70K	60K	53K	35K	8K	0.0	0.0	3.2M	4.6M	3M	1.1M	635K
Deferred Revenue	0.0	0.0	53K	0.0	0.0	0.0	0.0	0.0	5M	4.3M	10M	10M
Other Current Liabilities	28M	14.5M	4.1M	14.1M	24.6M	2.6M	4.5M	22.6M	80.7M	14.2M	5.6M	-4.3M
Total Current Liabilities	37.4M	35.2M	41.9M	66.8M	51.6M	28.1M	20.9M	38.6M	105.4M	35M	25.9M	11.9M
NON-CURRENT LIABILITIES
Long Term Debt	18K	24.9M	14.6M	19.8M	0.0	5.2M	10.2M	313.8M	279.4M	0.0	0.0	1.9M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	-8K	-99K	0.0	0.0	25.3M	29.6M	10M	10M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	8K	99K	0.0	0.0	194K	194K	194K	816K
Other Non-Current Liabilities	25.3M	0.0	0.0	1.4M	3.6M	8.2M	0.0	1M	918K	495K	367K	0.0
Total Non-Current Liabilities	25.3M	25M	14.6M	21.3M	3.6M	13.6M	10.2M	314.8M	305.8M	30.2M	10.6M	12.8M
Capital Lease Obligations	0.0	201K	108K	191K	98K	182K	83K	0.0	0.0	0.0	0.0	0.0
Total Liabilities	62.7M	60.2M	56.5M	88.2M	55.2M	41.6M	31.1M	353.4M	411.1M	65.2M	36.5M	24.6M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	178.2M
Common Stock	2K	2K	2K	2K	2K	1K	1K	42K	42K	36K	30K	25K
Additional Paid-In Capital	130.3M	107.1M	92.7M	85.5M	80.9M	5.2M	2.9M	0.0	0.0	0.0	0.0	0.0
Retained Earnings	-98.5M	-87M	-72.4M	-68.5M	-38.9M	5.1M	-163K	-745M	-553.4M	-250.1M	-161M	-82.6M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1M	-511K	-198K	-75K	-16K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	737M	703.5M	497.7M	346.6M	58M
Total Stockholders' Equity	31.9M	20.1M	20.4M	17M	42M	10.3M	2.8M	-9M	149.6M	247.4M	185.5M	153.6M
Total Equity	31.9M	20.1M	20.4M	17M	42M	10.3M	2.8M	-9M	149.6M	247.4M	185.5M	153.6M
SUMMARY
Total Liabilities & Equity	94.6M	80.2M	76.8M	105.2M	97.3M	51.9M	33.9M	344.3M	560.8M	312.6M	221.9M	178.2M
Total Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	211M	255.1M	234.7M	108.5M	108.3M
Total Debt	119K	25.7M	17.7M	23M	910K	9.9M	5.3M	313.8M	279.4M	0.0	0.0	1.9M
Net Debt	-24M	5.4M	-9.7M	-9M	-48.2M	1.7M	502K	208.8M	-16.5M	-41.8M	-107.2M	-53.4M
Shares Outstanding	24,390,625	24,390,625	24,390,625	24,390,625	24,390,625	24,390,625	24,390,625	24,390,625	24,390,625	24,390,625	24,390,625	24,390,625

SEC Filings

DERM - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 21, 2026	April 21, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 25, 2026	March 25, 2026	2026	View Filing
S-3 S-3 N/A	January 15, 2026	January 15, 2026		View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 26, 2025	September 25, 2025	2025	View Filing

Showing 1 to 10 of 77 filings

Related Guides

Blog Categories

Continue your DERM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.